Generation of a TLE3 heterozygous knockout human embryonic stem cell line using CRISPR-Cas9  by Bara, Anne M. et al.
Stem Cell Research 17 (2016) 441–443
Contents lists available at ScienceDirect
Stem Cell Research
j ourna l homepage: www.e lsev ie r .com/ locate /scrLab resource: Stem Cell LineGeneration of a TLE3 heterozygous knockout human embryonic stem cell
line using CRISPR-Cas9AnneM. Bara a, AngelicaMessana a, AmandaHerring a, Dane Z. Hazelbaker a, Kevin Eggan a,b, Lindy E. Barrett a,b,⁎
a Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
b Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USAN
In
P
C
D
O
Ty
Su
K
A
Li
In
E
⁎ Corresponding author.
E-mail address: lbarrett@broadinstitute.org (L.E. Barre
http://dx.doi.org/10.1016/j.scr.2016.09.008
1873-5061/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 7 September 2016
Accepted 14 September 2016
Available online 15 September 2016Here, we generated a monoallelic mutation in the TLE3 (Transducin Like Enhancer of Split 3) gene using CRISPR-
Cas9 editing in the human embryonic stem cell (hESC) line WA01. The heterozygous knockout cell line, TLE3-
447-D08-A01, displays partial loss of TLE3 protein expressionwhilemaintaining pluripotency, differentiation po-
tential and genomic integrity.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource table.ame of Stem Cell line TLE3-447-D08-A01
stitution Broad Institute of MIT and Harvard, Cambridge, MA
erson who created
resourceAnne M. Bara, Amanda Herring, Lindy E. Barrettontact person and
emailLindy Barrett, lbarrett@broadinstitute.org.ate archived/stock
dateMay 11, 2016rigin Human Embryonic Stem Cell Line WA01; NIH
Registration Number 0043.pe of resource Biological reagent: Genetically modiﬁed human
embryonic stem cell lineb-type Cell line
ey transcription
factorsN/Authentication Identity and purity of cell line conﬁrmed (Fig. 1)
nk to related literature http://www.ncbi.nlm.nih.gov/pubmed/9804556
http://www.ncbi.nlm.nih.gov/pubmed/25186908
http://www.ncbi.nlm.nih.gov/pubmed/21076418
http://www.ncbi.nlm.nih.gov/pubmed/24157548formation in public
databasesN/Athics Cell lines were used according to institutional
guidelines.Resource details
Here, we targeted exon 7 of TLE3 using CRISPR-Cas9 based genome
engineering (Ran et al. 2013) to generate a TLE3 heterozygous knockouttt).
. This is an open access article underhESC line, TLE3-447-D08-A01. This approach generated a 5 bp
monoallelic deletion in exon 7 of TLE3 (Fig. 1A). This deletion was pre-
dicted to shift the TLE3 reading frame, resulting in partial loss of TLE3 ex-
pression. To this end, the hESC line WA01 was transfected with
constructs expressing Cas9-D10A nickase coupled with puromycin re-
sistance and paired sgRNAs targeting exon 7 of TLE3. Cells were then se-
lectedwith puromycin and plated at clonal density to allow for targeted
colonies to emerge. We manually isolated a total of 94 individual colo-
nies, which were expanded in 96-well plates and then duplicated for
cell freezing and extraction of genomic DNA. To detect the presence of
frame-shift mutations, the region ﬂanking the predicted cut site of
exon 7 was PCR ampliﬁed, barcoded and deep-sequenced. Individual
colonies were then subcloned in order to distinguish heterozygous mu-
tant clones from mixed clones. Following a second round of deep se-
quencing, the putative TLE3 heterozygous clone, TLE3-447-D08-A01
(TLE3+/−), and a paired wild-type TLE3 clone, TLE3-447-E08-E02
(TLE3+/+), were expanded and banked for further analyses.
Western blot analysis revealed a near 50% loss of TLE3 protein ex-
pression in TLE3+/− cells relative to TLE3+/+ cells (Fig. 1B). Similarly, re-
verse transcription followed by quantitative PCR (RT-qPCR) analysis
showed a partial loss of TLE3 mRNA in the TLE3+/− line compared to
the TLE3+/+ line (Fig. 1C). Taken together, these results are consistent
with the 5 bp deletion in exon 7 leading to disruption of TLE3 expression
from the mutated allele. Genomic integrity of TLE3+/+ and TLE3+/− cell
lineswas conﬁrmed byG-banded karyotype analysis (Fig. 1D). Stem cell
colonies grown from both cell lines continued to express the
pluripotency markers OCT4, SOX2, SSEA-4 and TRA-1-60 (Fig. 1E) and
maintained three germ layer differentiation capacity, as evidenced by
expression of AFP (endoderm), SMA (mesoderm) and β-III Tubulin (ec-
toderm) following in vitro embryoid body differentiation (Fig. 1F).
Taken together, the TLE3heterozygous knockout hESC line described
here is karyotypically normal and retains pluripotency characteristics. Itthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Generation of the TLE3 heterozygous knockout hESC line TLE3-447-D08-A01 by CRISPR-Cas9 editing. (A) Paired Cas9 nickase approach to create a 5 bp deletion in exon 7 of TLE3.
Grey boxes denote sgRNA target sites and arrows show the location of Cas9 cleavage. (B)Western blot analysis reveals decreased levels of the TLE3 protein in TLE3-447-D08-A01 (TLE3+/−
) cells relative to TLE3-447-E08-E02 (TLE3+/+) cells. Relative enrichment of TLE3 protein was quantiﬁed by calculating pixel density of TLE3 signal relative to GAPDH signal from the blot
and normalizing the ratios of the TLE3+/+ samples to 1. Errors bars represent standard error of TLE1/GAPDH ratios from the two independent TLE3+/− sample lysates. (C) RT-qPCR analysis
reveals decreased relative TLE3 transcript levels in TLE3+/− cells compared to TLE3+/+ cells. Error bars represent standard error of the averaged normalized expression from two
independent experiments. (D) Chromosome analyses of TLE3+/+ and TLE3+/− lines shows a normal karyotype (46, XY). (E) Immunostaining of TLE3+/+ and TLE3+/− cells with
pluripotency markers OCT4, SOX2, SSEA-4, and TRA-1-60. (F) Immunostaining of embryoid bodies derived from TLE3+/+ and TLE3+/− cells reveals differentiation to all three germ
layers: AFP, endoderm; SMA, mesoderm; β-III Tubulin, ectoderm.
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velopment and disease.Materials and methods
Cell culture
The XY hESC line WA01 was obtained from WiCell (Thomson et
al. 1998) (www.wicell.org). Cells were grown in mTeSR1 medium
(Stem Cell Technologies 05850) on plates pre-coated with Geltrex
(Life Technologies A1413301) and maintained under standard
conditions (37 °C, 5% CO2). Cells were passaged using 1 mM EDTA
(Fluka 03690) in PBS or TrypLE Express (Life Technologies
12604021).CRISPR guide selection and cloning
CRISPR guides targeting exon 7 of TLE3were designed using http://
crispr.mit.edu. Oligonucleotides (IDT) corresponding to antisense
(CGGGGGGCCGTGTGTGGCAT) and sense (CAGTTGCCACCCCACCCGTC)
sgRNAs were cloned into a pU6-sgRNA vector (a gift from Feng Zhang,
Broad Institute) to generate the individual guide plasmids.Gene targeting and clonal selection
For electroporation, hESCs were pre-incubated with “1:1 medium”
composed of a 1:1 mixture of mTeSR1 medium and “hESC medium”
[hESC medium: KO DMEM (Gibco 10829-018) with 20% KOSR (Gibco
10828-028), 1% Glutamax (Gibco 35050-061), 1% MEM NEAA (Corning
443A.M. Bara et al. / Stem Cell Research 17 (2016) 441–44325-025-Cl), 0.1% 2-mercaptoethanol (Gibco 21985-023) and 20 ng/ml
bFGF (EMDMillipore GF003AF)] supplementedwith 10 μMROCK inhib-
itor (Υ-27632). For electroporation, 2.5 × 106 cells were re-suspended
in R Buffer, mixed with DNA and electroporated at 1050 V, 30 ms, 2
pulses using 100 μl tips (NEON, Life Technologies MPK10096) with
1.4 μg of each guide plasmid and 7 μg Cas9 nickase-puromycin plasmid
pX462 (Addgene Plasmid #62987).
Following electroporation, cells were dispensed into 10 cm Geltrex
coated plates in 1:1 medium plus ROCK inhibitor. After 24 h, cells
were treated with 1 μM puromycin (Sigma Aldrich P8833) for 24 h.
Cells were then maintained in 1:1 medium for 10 days to allow for col-
ony formation.
A total of 94 individual hESC colonies were manually picked and
seeded into Geltrex-coated 96-well plates in 1:1 medium plus ROCK in-
hibitor. Colonies were allowed to expand for 14 days and clones in 96-
well plates were then duplicated for cell freezing and genomic DNA ex-
traction. Clones were frozen in 96-well plates using 50% 1:1 medium
with ROCK inhibitor, 40% FBS (VWR SH30070.03) and 10% DMSO
(Sigma D2650). Genomic DNA was extracted overnight at 55 °C in
DirectPCR Lysis Reagent (Viagen 102-T) with Proteinase K (Roche
03115828001) followed by a 1 h 90 °C incubation.
For subcloning of hESCs, individual clones were thawed from 96-
well format into Geltrex-coated 6-well plates in 1:1 medium plus
ROCK inhibitor. Cells were thenmaintained in 1:1medium to allow col-
onies to emerge. Individual hESC colonies were then manually picked,
expanded, screened and analysed, as described above.
Screening and sequence analysis
Primers containing Illuminamultiplexing adapters (Ilumina) and spe-
ciﬁc to exon 7 of TLE3 (F: ACACTCTTTCCCTACACGACGCTCTTCCGATCT
GCCAGCAGCCCGGAG and R: GTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCTAGCTGTACTCACCACCGACT; underlined = adaptor sequence)
were used to PCR amplify a 160 bp TLE3 sequencing amplicon with Q5
Hot Start High-Fidelity Master Mix (NEB M04945). A second round of
PCR ampliﬁcation was performed on the 160 bp TLE3 amplicon used to
incorporate well-speciﬁc barcode IDs (Broad Institute). Barcoded PCR
products were pooled and gel-puriﬁed (Zymo Research D4008), run on
a 2100 BioAnalyzer (Agilent Technologies) for quality assessment and
submitted for MiSeq paired-end deep sequencing (Broad Institute). Se-
quencing results were analysed using the OutKnocker indel-calling pro-
gram (www.OutKnocker.org) (Schmid-Burgk et al. 2014).
Embryoid body differentiation
Embryoid bodies (EBs) were generated as described (Klim et al.
2010). Brieﬂy, hESCs were grown in ultra low-attachment ﬂasks in “EB
medium” [composed of IMDM (Life Technologies 12440079), 15% FBS,
1% NEAA and 0.1 mM 2-mercaptoethanol] for 2.5 weeks. EBs were
then seeded into Geltrex-coated 12-well plates and allowed to differen-
tiate under adherent conditions in EB medium for one additional week
prior to ﬁxation and immunostaining. For neuron generation, EBs were
treated with dual SMAD inhibition (10 μM SB431542 and 100 nM
LDN193189).
Western blot analysis
Two independently grown replicates of TLE3-447-D08-A01 and
TLE3-447-E08-E02 were lysed using Pierce IP lysis buffer (Life Technol-
ogies 87787) with protease inhibitors (Sigma Aldrich 11836153001).
20 μg protein as determined by Pierce BCA Protein Assay kit (Thermo
Scientiﬁc 23227) was loaded onto Bolt 4-12% Bis-Tris Plus gels(Invitrogen). Gels were dry blotted to nitrocellulose membranes (iBlot
2 NCMinistacks, Invitrogen) by the iBlot 2 transfer system (Invitrogen).
The following antibodies were used: TLE3 (Abcam ab94972; 1:1000),
GAPDH (EMD MAB374; 1:2000), α-rabbit HRP-linked F(ab′)2 (GE Life
Sciences NA9340; 1:5000) and α-mouse HRP-linked F(ab’)2 (GE Life
SciencesNA9310; 1:5000). Blotswere visualized on a ChemiDocMP Im-
aging System (BioRad) using a SuperSignal West Femto kit (Pierce).
Pixel density quantiﬁcation of TLE3 and GAPDH was performed with
ImageJ software (https://imagej.nih.gov/ij/).
RT-qPCR analysis
Total RNA from two independently grown replicates of TLE3-447-
D08-A01 and TLE3–447-E08-E02 was extracted using an RNeasy Mini
Kit (Qiagen). Reverse Transcription cDNA synthesis reactions were per-
formed on 0.2 μg−2 μg total RNA with iScript cDNA synthesis kit (Bio-
Rad) according tomanufacturer instructions. Quantitative PCR reactions
were performed using iTaq Universal SYBR Green Supermix (BioRad)
with QuantiTect qPCR primers speciﬁc to TLE3 exons 13/14/15 (Qiagen
QT00045003) and quantiﬁed by the ΔΔCt method on a CFX384 Real-
Time System (Bio-Rad).
Immunostaining
hESC colonies and EBs were ﬁxed with 4% paraformaldehyde in PBS
for 15mins at room temperature, blocked and permeabilized with 0.1%
TritonX-100 and 4% serum in PBS for 1 h and incubated with the appro-
priate primary antibody. Following primary antibody incubation, cells
were washed with PBS and incubated with the appropriate secondary
antibody (Alexa Fluor 488 or 594, 1:500, Invitrogen) for 1 h. Cells
were then washed with PBS and incubated with DAPI before imaging
at 20× magniﬁcation. The following primary antibodies were used:
OCT4 (R&D Systems AF1759; 1:250), SSEA-4 (SCBT SC21704; 1:250),
TRA-1-60 (SCBT SC21705; 1:200), SOX2 (R&D Systems MAB2018;
1:200), AFP (Sigma A8452; 1:250), SMA (Sigma A2547; 1:2000), β-III
Tubulin (R&D Systems MAB1195; 1:3000).
Analysis of genomic integrity
Cytogenetic analysis was performed by Cell Line Genetics (www.
clgenetics.com) on twenty G-banded metaphase cells from each cell
line.
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